Abstract submission information

Abstracts should present new research or developing information on STI’s and HIV infection and AIDS and related conditions. Abstracts are selected on the basis of their medical and scientific significance, timeliness, quality of data and methodology, adherence to specific format requirements, and other criteria described here.

Important dates

•    General abstract submission opens: May 1, 2020 
•    Scholarship application submission opens: May 1, 2020
•    Deadline for submitting general abstracts and scholarships: July 31, 2021
•    Late-breaking abstract submission opens: October 15, 2021

•    Abstract evaluation deadline: September 31, 2021

•    Deadline for submitting late-breaking abstracts: October 15, 2021

General Abstract Submission
General abstract submission is now open. Please submit through the website www.iusti2020bangkok.com

Abstract Content
Each abstract must include the 6 elements: title, author names with professional affiliations, background, methods, results, and conclusions. Abstracts may also include 1 table or 1 figure. In addition, the submitting author must provide the following information: whether the abstract has been previously published or presented and if so, where; the abstract category

Character Allowances
Section headings (ie, Background, Methods, Results, and Conclusions), are not included in the abstract body character count. Do not include these headings in the body of the submitted text. Please use the counters on the abstract submission page to track your character count.


Character limits are as follows:

  • Title: Up to 125 characters, including spaces.

  • Body: Up to 2600 characters, cumulative, including spaces.


The abstract title should be concise and clearly convey the subject of the abstract.

  • Maximum length: 125 characters, including spaces.

  • Example: A Randomized Controlled Trial of The Impact of Drug A and Drug B in Treating HIV

Author Names and Affiliations
Up to 15 authors may be included on each abstract, (including a research team or group, if applicable). If you wish to include the name of a research team or group as the 15th author, follow the instructions on the abstract submission form. Please DO NOT enter the names of additional individual authors in the research group field.

Authors listed on the abstract should conform to the International Committee of Medical Journal Editors (ICMJE) recommendations for authorship:

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND

  2. Drafting the work or revising it critically for important intellectual content; AND

  3. Final approval of the version to be published; AND

  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Author Affiliations:

Indicate each author’s professional affiliation by selecting the institution from the list provided in the abstract submission system. The list may be filtered beginning with the first word of the institution name. In general, the list does not use abbreviations for institutions, although there are some exceptions (eg, CDC, US CDC, NIH, CHU, and INSERM are used as abbreviations). Department names and school names are not used unless they are part of the institution name (eg, San Francisco Department of Public Health).

Research Collaborators:

Individuals who are not listed as co-authors on an abstract may be considered research collaborators if they contributed substantively and measurably to the scientific development or execution of the project. Research collaborators should meet most of the same authorship criteria described the ICMJE recommendations above.

Abstract Sections
Abstracts are divided into 4 sections (described below): Background, Methods, Results, and Conclusions. Text submitted should one paragraph per section.


Briefly and clearly describe the hypothesis of the study. Why was the study conducted?


Detail the experimental methods and processes employed in the study. What did you do?


Describe the precise findings of the study; promises of results “to be determined” are not acceptable. Describe what you found and include data


Describe logically sound conclusions and reliable inferences drawn from the study results. Why are the study’s findings important?

Special Notes on Abstract Content

Trade Names
Trade names for drugs should not be used in abstracts. Refer to drugs by their nonproprietary names.

Statements of Support
Statements of grant support or funding statements may not be included in the abstract text (eg, Study was funded by NIH). Statements of support may be included in the presentation of the abstract at IUSTI 2020 Bangkok, if accepted.

Abstracts Describing Clinical Trials
Presentations from randomized trials and cohorts should follow the ICMJE guidelines, including reporting of study designs, (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. See: ICMJE Preparing for Submission.
Of particular note, please consider whether there is substantive evidence of differences in effect by sex or other key demographic groups. If so, a stratified analysis should be made available during the presentation of the abstract at IUSTI 2020 Bangkok. Please also note whether the study is ongoing or completed and whether the results are preliminary or final.

Case Reports

Investigators are invited to submit abstracts which describe interesting, unusual, or complex clinical cases of STI or STI-associated syndromes.  These cases will be presented and discussed by an expert panel of clinicians who will review salient issues of epidemiology, clinical presentation, differential diagnosis, and management options.  Cases should reflect recent patient encounters which highlight the complexities of STI clinical decision-making in current practice.  Abstracts should be submitted according to the general guidelines described above.

Submitting Author Responsibilities
The person who submits an abstract is responsible for the following:

  • Assuring that If accepted, the presenting author will present the abstract as designated by the Scientific Program Committee (ie, as an oral or poster presentation)

  • Ensuring that financial relationships with commercial entities have been disclosed for the presenting author, his or her spouse or partner, and institution

  • Assuring that if the presenting author is replaced with a new presenter, the new presenter will disclose financial relationships with commercial entities for self, spouse or partner, and institution.  The final abstract submission must include disclosure information for the author who will present at Scientific Committee.

  • Providing complete and accurate contact and affiliation information for ALL coauthors; correct email addresses are essential

  • Assuring that ALL co-authors have reviewed and approved the abstract’s content

  • Give permission for the presentation to be videotaped and/or recorded and the abstract to be published in the Abstract eBook, and other related conference materials

  • If accepted as a poster presentation, providing an electronic version of the poster

  • If an abstract is accepted, the presenting author is expected to register for the conference.

Changes in Presenting Author
The author noted as the presenting author on an abstract is responsible for delivering either the oral or poster presentation if the abstract is accepted. In case of an emergency, an alternate may take the presenting author’s place. The new presenting author must update the abstract submission to disclose information for his or herself, his or her spouse or partner, and institution. The new presenter must be listed as a co-author on the abstract and must be registered and accepted for attendance at the organizer.

Disclosure of Financial Relationships
The submitting author is responsible for the disclosure of financial relationships with commercial entities for the following:

  • Presenting author

  • Spouse or partner of the presenting author

  • Grants to the presenting author, spouse, or partner paid to their institution

  • New presenting author (if applicable), including spouse or partner and institution

See ACCME definition of commercial interest for more information.


21st IUSTI Congress

Joint meeting with 21st IUSTI A-P Branch Conference

Dec 1 - 4, 2021 Bangkok, Thailand



Consortium of Thai Training Institutes for STDs and AIDS (COTTISA) 

Bangkok Thailand

Contact information

General Information                secretariat@iusti2020bangkok.com

Sponsorship Information           sponsorship@iusti2020bangkok.com

Abstract Information               abstract@iusti2020bangkok.com

Register Information               registration@iusti2020bangkok.com

Tour Information                     tour@iusti2020bangkok.com

Visa Information                      visa@iusti2020bangkok.com

Iconsiam call center                Tel: (66+) 2 495 7080

Copyright © 2019 World IUSTI Bangkok 2021 | Powered by World IUSTI Bangkok 2021